Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Research

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2–59 Months of Age, Spain

Sergi HernándezComments to Author , Fernando Moraga-Llop, Alvaro Díaz, Mariona F. de Sevilla, Pilar Ciruela, Carmen Muñoz-Almagro, Gemma Codina, Magda Campins, Juan José García-García, Cristina Esteva, Conchita Izquierdo, Sebastià González-Peris, Johanna Martínez-Osorio, Sonia Uriona, Luis Salleras, and Ángela Domínguez
Author affiliations: Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain (S. Hernández, P. Ciruela, C. Izquierdo); Hospital Universitari Vall d’Hebron, Barcelona (F. Moraga-Llop, M. Campins, S. González-Peris); Hospital de Nens, Barcelona (A. Díaz); Hospital Sant Joan de Déu Barcelona, Barcelona (M.F. de Sevilla, C. Muñoz-Almagro, J.J. García-García, C. Esteva, J. Martínez-Osorio); Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain (M.F. de Sevilla, C. Muñoz-Almagro, J.J. García-García); CIBER de Epidemiología y Salud Pública, Madrid, Spain (P. Ciruela, J.J. García-García, C. Esteva, L. Salleras, Á. Domínguez); Universitat Internacional de Catalunya, Barcelona (C. Muñoz-Almagro); Vall d’Hebron Institut de Recerca, Barcelona (M. Campins, S. Uriona); Universitat de Barcelona, Barcelona (L. Salleras, Á. Domínguez)

Main Article

Table 3

Characteristics of cases of invasive pneumococcal disease in patients 2–59 months of age with and without vaccine failure, Catalonia, Spain, 2012–2016

Variable Vaccine failure, no. (%), n = 24 No vaccine failure, no. (%), n = 156 OR (95% CI) p value
Sex
F 8 (33.3) 58 (37.2) Referent
M
 16 (66.7)
 98 (62.8)
 1.18 (0.48–2.94)
 0.716
Age group
2–23 mo 9 (37.5) 73 (46.8) Referent
24–59 mo
 15 (62.5)
 83 (53.2)
 1.46 (0.60–3.55)
 0.395
Clinical form
Meningitis 0 16 (10.3) 0 0
Septic shock 0 4 (2.6) 0 0
Uncomplicated pneumonia 1 (4.2) 26 (16.7) 0.22 (0.03–1.68) 0.134
Complicated pneumonia 21 (87.5) 80 (51.3) 6.65 (1.91 −23.21) 0,001
Occult bacteremia 0 20 (12.8) 0 0
Other
 2 (8.3)*
 10 (6.4)†
1.33 (0.27–6.46)
 0.664
Pneumonia complication
Empyema 15 (71.4) 62 (77.5) 0.73 (0.25–2.14) 0.561
Pleural effusion 3 (14.3) 23 (28.8) 0.41 (0.11–1.54) 0.263
Necrotizing pneumonia
 8 (38.1)
 18 (22.5)
 2.12 (0.76–5.91)
 0.146
Intensive care unit admission 2 (8.3) 35 (22.4) 0.31 (0.07–1.40) 0.173
Sequelae at discharge 3 (12.5) 20 (11.9) 0.96 (0.26–3.53) 1.000
Underlying disease
 0
 9 (5.8)
 0
 0
Diagnostic technique
PCR only 19 (79.2) 66 (42.3) 6.62 (1.47–29.82) 0.014
Culture only 3 (12.5) 44 (28.2) 1.57 (0.25–9.84) 0.631
PCR + culture
 2 (8.3)
 46 (29.5)
 Referent
Breastfeeding 22 (91.7) 125 (81.2) 2.55 (0.57–11.47) 0.260
School or daycare attendance 20 (83.3) 102 (66.2) 2.55 (0.83–7.85) 0.104
Respiratory infection previous month 17 (70.8) 88 (57.1) 1.82 (0.71–4.65) 0.205
Recurrent otitis media 5 (20.8) 19 (12.3) 1.87 (0.62–5.59) 0.257

*Osteoarticular infection (1); mastoiditis (1).
†Osteoarticular infection (5); mastoiditis (4); orbital cellulitis (1).

Main Article

Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external